Furthermore, combinations of CEL_Amide with BCR::ABL-targeting TKIs yield synergy in vitro and in vivo, encouraging further preclinical and clinical testing of LIMK1/2 inhibitors in BCR::ABL+ B-ALL. This evidence concerns the gene LIMK1 and acute lymphoblastic leukemia.